Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Townsquare Capital LLC

Townsquare Capital LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 28.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,109 shares of the life sciences company’s stock after buying an additional 2,872 shares during the quarter. Townsquare Capital LLC’s holdings in Illumina were worth $1,710,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in Illumina during the 2nd quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV boosted its position in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina in the second quarter worth $61,000. Finally, Private Trust Co. NA increased its position in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of analyst reports. Daiwa America raised Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Robert W. Baird lifted their price target on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Barclays increased their target price on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada boosted their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $144.15 on Monday. Illumina, Inc. has a one year low of $99.23 and a one year high of $156.66. The stock has a market cap of $22.86 billion, a PE ratio of -14.47 and a beta of 1.13. The business’s fifty day moving average price is $141.88 and its two-hundred day moving average price is $126.03. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the business posted $0.33 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis. On average, analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.